INtranasal OXyTocin for the Treatment of Autism Spectrum Disorders (INOXT)
INtranasal OXyTocin for the Treatment of Autism Spectrum Disorders (ASD)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Ontario
-
Hamilton, Ontario, Canada, L8S 4K1
- St. Joseph's Healthcare Hamilton
-
Toronto, Ontario, Canada, M4G 1R8
- Holland Bloorview Kids Rehabilitation Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria
- Male or female outpatients 18-45 years of age, inclusive
- Meet Diagnostic and Statistical Manual of Mental Disorders. Diagnostic and Statistical Manual (DSM-V) criteria will be established by a clinician with expertise with individuals with ASD. Best estimate Diagnosis will be reached using DSM-V criteria, the Autism Diagnostic Observation Schedule (ADOS) and the Autism Diagnostic Interview (ADI-R).
- Have a Clinical Global Impression-Severity (CGI-S) score ≥ 4 (moderately ill) at Screening.
- Verbal scale Intelligence Quotient (IQ) ≥ 70
- If already receiving stable concomitant medications affecting behavior, have stable regimens with no changes during the preceding 1 month prior to Screening (with the exception of fluoxetine, where a period of 6 weeks is needed), and will not electively initiate new or modify ongoing medications for the duration of the study
- If already receiving stable non-pharmacological educational, behavioral, and/or dietary interventions, have continuous participation during the preceding 3 months prior to Screening, and not electively initiate new or modify ongoing interventions for the duration of the study
- Have normal physical examination and laboratory test results at screening. If abnormal, the finding(s) must be deemed clinically insignificant by the Treating Clinician.
- Ability to speak and understand English sufficiently to allow for the completion of all study assessments
- Ability to obtain written informed consent from the subject (if developmentally appropriate), or ability to obtain written informed consent from their surrogate decision maker (SDM), if the subject is unable to provide consent.
Exclusion Criteria
- Patients born prior to 28 weeks gestational age
- Patients with a primary psychiatric diagnosis other than ASD
- Patients with a medical history of neurological disease, including, but not limited to, epilepsy/seizure disorder, movement disorder, tuberous sclerosis, fragile X, and any other known genetic syndromes, or known abnormal brain MRI/structural lesion. Exceptions: 1) simple febrile seizures, 2) epilepsy/ seizure free for at least 2 years prior to Screening
- Pregnant female patients, sexually active female patients on hormonal birth control and sexually active females who do not use at least two types of non-hormonal birth control
- Patients with evidence or history of malignancy or any significant hematological, endocrine, cardiovascular (including any rhythm disorder), respiratory, renal, hepatic, or gastrointestinal disease
- Patients with one or more of the following: HIV, Hepatitis B virus, Hepatitis C virus, hemophilia (bleeding problems, recent nose and brain injuries), abnormal blood pressure (hypotension or hypertension), drug abuse, immunity disorder or severe depression.
- Patients unable to tolerate venipuncture procedures for blood sampling
- Patients who are currently taking oxytocin or have taken intranasal oxytocin in the past with no response
- Patients with a sensitivity to oxytocin or any components of its formulation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
24 IU taken twice daily (BID), in the morning and at noon/early afternoon
|
|
Active Comparator: Intranasal Oxytocin
|
24 IU taken twice daily (BID), in the morning and at noon/early afternoon
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Efficacy of intranasal oxytocin vs. placebo on social function in adults with ASD
Time Frame: 12 weeks
|
This will be measured by the Clinical Global Impressions - Improvement Scale - Social (CGI-I-Social).
|
12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Efficacy of intranasal oxytocin vs. placebo on a continuous measure of social cognition in adults with ASD
Time Frame: 12 weeks
|
This will be measured by the Revised Eyes Test
|
12 weeks
|
|
Efficacy of intranasal oxytocin vs. placebo on a continuous measure of social function in adults with ASD
Time Frame: 12 weeks
|
This will be measured by the Vineland Adaptive Behavior Scale (VABS-II)
|
12 weeks
|
|
Efficacy of intranasal oxytocin vs. placebo on a continuous measure of social responsiveness in adults with ASD
Time Frame: 12 weeks
|
This will be measured by the Social Responsiveness Scale (SRS-2)
|
12 weeks
|
|
Efficacy of intranasal oxytocin vs. placebo on a continuous measure of social responsiveness in adults with ASD
Time Frame: 12 weeks
|
This will be measured by the Aberrant Behavior Checklist (ABC)
|
12 weeks
|
|
Safety and tolerability of intranasal oxytocin in adults with ASD
Time Frame: 12 weeks
|
This will be measured by the Safety Monitoring Uniform Report Form (SMURF)
|
12 weeks
|
|
Safety and tolerability of intranasal oxytocin in adults with ASD
Time Frame: 12 weeks
|
This will be measured by the Clinical Global Impressions - Improvement Scale - Global (CGI-I-Global)
|
12 weeks
|
|
Efficacy of intranasal oxytocin vs. placebo on quality of life
Time Frame: 12 weeks
|
This will be measured by the World Health Organization Quality of Life Survey (WHOQOL-BREF)
|
12 weeks
|
|
Efficacy of intranasal oxytocin vs. placebo on anxiety
Time Frame: 12 weeks
|
This will be measured by the Symptom Checklist 90-Revised (SCL-90-R)
|
12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Evdokia Anagnostou, M.D., Holland Bloorview Kids Rehabilitation Hospital
- Principal Investigator: Marc Woodbury-Smith, M.D., McMaster University
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- INOXT-10-2013
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.